Breakingviews
Top Commentary
Obesity drug boom has a new pecking orderEli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs Mounjaro and Zepbound, is trading at more than double the valuation multiple of Wegovy maker Novo Nordisk , whereas once the two were equally richly valued. It will be hard for the Danish group to close the gap.
